About Wilbur Salt OS
We are building the first synthetic pharmaceutical enterprise—an AI-native operating system designed to act as an externally licensed cognition engine for the world's largest pharma companies.
About Salt AI
Salt AI is founded by industry veterans in high-performance computing (HPC), artificial intelligence, and life sciences. We are dedicated to building enterprise cognition engines that extend the cognitive capacity of pharmaceutical organizations—allowing them to think at a scale and speed previously impossible.
Our platform contains thousands of synthetic coworkers, each mapped to a defined domain role and governed by resume-driven execution protocols. These are not LLMs run wild, but structured agents bound by domain-specific job specs, methodological boundaries, and interaction standards.
Salt's architecture prioritizes model-agnostic orchestration—integrating best-in-class AI components and continuously swapping underperforming modules. The result is meaningful breakthroughs and competitive advantage for your organization.
Our Story
Bringing a new pharmaceutical product to market costs $1–2 billion and takes a decade or longer. Fewer than 5% of drug candidates achieve regulatory approval. The industry spends over $250 billion annually on R&D, yet attrition rates remain devastating at every stage.
Wilbur Salt OS was born from a simple observation: the pharmaceutical enterprise has become too complex for the human mind to model alone. Traditional consulting delivers static PowerPoints obsolete on delivery. Internal AI initiatives fare no better—70% of pharma digital projects fail to deliver real outcomes.
We built the V-Org Engine to bridge that gap. By creating a synthetic pharmaceutical enterprise—thousands of AI coworkers running in parallel to the real organization—we provide the "flight simulator" that executives have been missing. A new way to think in pharma organizations. One driven not by bandwidth, but by possibility.
Meet Our Team
Industry veterans in high-performance computing, artificial intelligence, and life sciences working together to build the first synthetic pharmaceutical enterprise.
Strategic Advisors
Former CIO, Merck
Advising on enterprise data integration and security architecture.
Prof. of Complex Systems, MIT
Guiding the development of our core simulation algorithms.